We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02077231
Recruitment Status : Completed
First Posted : March 4, 2014
Last Update Posted : March 5, 2014
Information provided by (Responsible Party):
Xiaodong Zhou, Shanghai Jinshan Hospital

Brief Summary:
Most of the patients under long application of anti-glaucoma eyedrops endure severe ocular surface irritation, which interrupt their quality of life a lot. Lots of studies aimed to search for new drugs for therapy. The investigators hypothesized that the artificial tears containing vitamin A or carbomer may be a great substitute. Both of the two drugs were in common use and had already been tested in animals.

Condition or disease Intervention/treatment Phase
Primary Open-angle Glaucoma Drug: Vitamin A Drug: carbomer eye gel Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : September 2011
Actual Primary Completion Date : February 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma Vitamin A

Arm Intervention/treatment
Experimental: vitamin A palmitate eye gel
0.1% vitamin A palmitate; Sinqi, Shenyang, China
Drug: Vitamin A
use one drop in the eye
Other Name: vitamin A palmitate eye gel

Experimental: carbomer eye gel
0.2% Carbomer 940; Bausch & Lomb, Aschheim, Germany
Drug: carbomer eye gel
use one drop in the eye
Other Name: Carbomer Eye Drops

Primary Outcome Measures :
  1. change of the density of conjunctival goblet cells [ Time Frame: change from Baseline in goblet cell density at 6 months ]

Secondary Outcome Measures :
  1. tear film parameters changes in patients [ Time Frame: change from baseline in TBUT and Schirmer test at 6 months ]
  2. changes of ocular irritation in patients [ Time Frame: change from baseline in OSDI scores at 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- diagnosed primary open-angle glaucoma or normal tension glaucoma patients with prostaglandin analogs treatment for more than one year.

Exclusion Criteria:

  1. any systemic diseases which may cause ocular damage;
  2. previous ocular trauma or surgery;
  3. contact lens wear history in previous 6 months;
  4. application of any artificial tears 3 months ago;
  5. allergic to any of the drugs we used during examination.
Layout table for additonal information
Responsible Party: Xiaodong Zhou, Professor of Ophthalmology, Shanghai Jinshan Hospital
ClinicalTrials.gov Identifier: NCT02077231    
Other Study ID Numbers: GlaucomaVitaminA
First Posted: March 4, 2014    Key Record Dates
Last Update Posted: March 5, 2014
Last Verified: March 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Vitamin A
Retinol palmitate
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents
Anticarcinogenic Agents
Antineoplastic Agents